-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $20 Price Target

Benzinga·05/15/2025 15:31:33
Listen to the news
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $20 price target.